摘要
目的:观察多黏菌素B联合头孢哌酮钠舒巴坦钠与替加环素治疗老年多重耐药菌肺部感染患者的效果。方法:选取2020年1月至2023年1月该院收治的90例老年多重耐药菌肺部感染患者进行前瞻性研究,按照随机数字表法分为观察组与对照组各45例。对照组采用注射用替加环素联合注射用头孢哌酮钠舒巴坦钠治疗,观察组在对照组基础上增加注射用硫酸多黏菌素B治疗,比较两组临床疗效、症状缓解时间、肺功能指标[第1秒用力呼气容积(FEV_(1))、FEV_(1)与用力肺活量比值(FEV_(1)/FVC)、肺活量]水平、血清炎性指标[C反应蛋白(CRP)、降钙素原]水平和不良反应发生率。结果:观察组治疗总有效率为93.33%,明显高于对照组的77.78%,差异有统计学意义(P<0.05);观察组咳嗽、咳痰、肺部啰音、发热等症状缓解时间均短于对照组,差异有统计学意义(P<0.05);治疗后,两组FEV_(1)、FEV_(1)/FVC、肺活量水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组血清CRP、降钙素原水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:多黏菌素B联合头孢哌酮钠舒巴坦钠与替加环素治疗老年多重耐药菌肺部感染患者可提高治疗总有效率和肺功能指标水平,缩短症状缓解时间,降低炎性指标水平,效果优于头孢哌酮钠舒巴坦钠联合替加环素治疗。
Objective:To observe effects of Polymyxin B,Cefoperazone sodium and Sulbactam sodium,and Tigecycline triple therapy on elderly patients with multi-drug resistant bacteria pulmonary infection.Methods:A prospective study was conducted on 90 elderly patients with multi-drug resistant bacteria pulmonary infection admitted to this hospital from January 2020 to January 2023.They were divided into observation group and control group according to the random number table method,45 cases in each.The control group was treated with Tigecycline for injection combined with Cefoperazone sodium and Sulbactam sodium for injection,while the observation group was treated with Polymyxin B sulfate for injection on the basis of those of the control group.The efficacy,the symptom relief time,the pulmonary function index levels[forced expiratory volume in the first second(FEV_(1)),FEV_(1)/forced vital capacity ratio(FEV_(1)/FVC),vital capacity],the serum inflammatory indexes[C-reactive protein(CRP),procalcitonin]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 93.33%,which was significantly higher than 77.78%in the control group,and the difference was statistically significant(P<0.05).The symptom relief time such as cough,expectoration,lung rales and fever in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FEV_(1),FEV_(1)/FVC and vital capacity in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum CRP and procalcitonin in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant dif
作者
樊红岩
马高峰
高彪
FAN Hongyan;MA Gaofeng;GAO Biao(Sui County People’s Hospital,Department of Clinical Laboratory,Shangqiu 476900 Henan,China;Department of Respiratory and Critical Care Medicine,Shangqiu 476900 Henan,China;Comprehensive ICU,Shangqiu 476900 Henan,China)
出处
《中国民康医学》
2023年第20期89-91,共3页
Medical Journal of Chinese People’s Health
关键词
老年
肺部感染
多重耐药菌
替加环素
头孢哌酮钠舒巴坦钠
多黏菌素B
肺功能
Elderly
Pulmonary infection
Multidrug-resistant bacteria
Tigecycline
Cefoperazone sodium and Sulbactam sodium
Polymyxin B
Lung function
